First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in Advanced NSCLC With 1% or Greater Tumor PD-L1 Expression: Patient-Reported Outcomes From CheckMate 227 Part 1
| Autor: | Reck, Martin, Ciuleanu, Tudor-Eliade, Lee, Jong-Seok, Schenker, Michael, Audigier-Valette, Clarisse, Zurawski, Bogdan, Linardou, Helena, Otterson, Gregory A., Salman, Pamela, Nishio, Makoto, de la Mora Jimenez, Emmanuel, Lesniewski-Kmak, Krysztof, Albert, István, Ahmed, Samreen, Syrigos, Konstantinos, Penrod, John R., Yuan, Yong, Blum, Steven I., Nathan, Faith E., Sun, Xiaowu, Moreno-Koehler, Alejandro, Taylor, Fiona, O'Byrne, Kenneth John |
|---|---|
| Zdroj: | In Journal of Thoracic Oncology April 2021 16(4):665-676 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|